Seerapani Gopaluni Selected Research

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

3/2023	A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol.
1/2022	Alemtuzumab for refractory primary systemic vasculitis-a randomised controlled dose ranging clinical trial of efficacy and safety (ALEVIATE).
1/2021	Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models.
1/2021	Slowly progressive anti-neutrophil cytoplasmic antibody-associated renal vasculitis: clinico-pathological characterization and outcome.
8/2019	Evaluation of PR3-ANCA Status After Rituximab for ANCA-Associated Vasculitis.
1/2019	Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis.
1/2019	Effect of Disease Activity at Three and Six Months After Diagnosis on Long-Term Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
1/2019	A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis.
12/2018	Publisher Correction: B cell therapy in ANCA-associated vasculitis: current and emerging treatment options.
10/2018	B cell therapy in ANCA-associated vasculitis: current and emerging treatment options.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Seerapani Gopaluni Research Topics

Disease

12	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 03/2023 - 01/2016
11	Vasculitis (Vasculitides) 01/2022 - 01/2017
5	Infections 01/2022 - 10/2018
3	Glomerulonephritis 08/2022 - 01/2019
2	Systemic Vasculitis 01/2022 - 01/2021
2	Autoimmune Diseases (Autoimmune Disease) 01/2021 - 10/2018
1	Reinfection 01/2021
1	COVID-19 01/2021
1	Agammaglobulinemia (Hypogammaglobulinemia) 01/2021
1	Disease Progression 01/2021
1	Granulomatosis with Polyangiitis (Wegener's Granulomatosis) 10/2019
1	Proteinuria 01/2019
1	Respiratory Tract Infections (Respiratory Tract Infection) 10/2018
1	Bronchiectasis 10/2018
1	Chronic Obstructive Pulmonary Disease (COPD) 10/2018
1	Vomiting 11/2016
1	Headache (Headaches) 11/2016
1	Fatigue 11/2016
1	Syncope (Fainting) 11/2016
1	Nausea 11/2016
1	Dyspepsia (Indigestion) 11/2016
1	Sleepiness 11/2016
1	Lethargy 11/2016
1	Epistaxis (Nosebleed) 05/2009
1	Superior Vena Cava Syndrome (Superior Vena Cava Obstruction) 05/2009

Drug/Important Bio-Agent (IBA)

9	Rituximab (Mabthera)FDA Link 03/2023 - 01/2017
9	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 08/2022 - 01/2016
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021 - 01/2018
4	GlucocorticoidsIBA 01/2021 - 01/2019
2	Alemtuzumab (Campath)FDA Link 01/2022 - 10/2018
1	belimumabIBA 03/2023
1	Immunoglobulin G (IgG)IBA 01/2021
1	Oxygen (Dioxygen)IBA 01/2021
1	Immunoglobulins (Immunoglobulin)IBA 01/2021
1	Proteins (Proteins, Gene)FDA Link 10/2019
1	Myeloblastin (Proteinase 3)IBA 08/2019
1	CreatinineIBA 01/2019
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2019
1	AutoantibodiesIBA 10/2018
1	Sulfamethoxazole Drug Combination Trimethoprim (Co-Trimoxazole)FDA LinkGeneric 10/2018
1	CytokinesIBA 10/2018
1	B-Cell Activating FactorIBA 10/2018
1	Azathioprine (Imuran)FDA LinkGeneric 01/2017
1	VitaminsIBA 11/2016
1	Caffeine (No Doz)FDA LinkGeneric 11/2016
1	Levodopa (L Dopa)FDA LinkGeneric 11/2016
1	ropinirole (Requip)FDA LinkGeneric 11/2016

Therapy/Procedure

5	Therapeutics 03/2023 - 01/2017
2	Remission Induction 08/2019 - 01/2017
2	Cell- and Tissue-Based Therapy (Cell Therapy) 12/2018 - 10/2018
1	Immunotherapy 03/2023
1	Central Venous Catheters 05/2009